Table 3.
Vaccine effectiveness against hospitalization for the BNT162b2 (Pfizer-BioNTech) booster vaccines in England by age group
| Age group (years) | Primary course (≥175 days after dose 2) | Booster | Interval since booster (days) | Controls | Cases | VE (unvaccinated base) (95% CI) |
|---|---|---|---|---|---|---|
| 18-49 | Unvaccinated | 111,292 | 1,366 | Baseline | ||
| ChAdOx1-S | None | 42,032 | 171 | 85.7 (82.9–88.1) | ||
| ChAdOx1-S | Any | 0–1 | 1,244 | 5 | 89.2 (73.7–95.5) | |
| ChAdOx1-S | Any | 2–6 | 2,181 | 6 | 93.0 (84.2–96.9) | |
| ChAdOx1-S | BNT162b2 | 7–13 | 2,498 | 6 | 93.8 (86.1–97.3) | |
| ChAdOx1-S | BNT162b2 | 14–34 | 4,284 | 4 | 97.5 (93.3–99.1) | |
| ChAdOx1-S | BNT162b2 | 35–69 | 1,279 | 2 | 94.7 (78.7–98.7) | |
| BNT162b2 | None | 70,347 | 72 | 94.8 (93.3–96.0) | ||
| BNT162b2 | Any | 0–1 | 2,398 | 6 | 89.9 (77.3–95.5) | |
| BNT162b2 | Any | 2–6 | 5,275 | 3 | 97.8 (93.1–99.3) | |
| BNT162b2 | BNT162b2 | 7–13 | 7,552 | 2 | 98.9 (95.8–99.7) | |
| BNT162b2 | BNT162b2 | 14–34 | 16,531 | 5 | 98.8 (97.2–99.5) | |
| BNT162b2 | BNT162b2 | 35–69 | 8,697 | 2 | 99.1 (96.4–99.8) | |
| ≥50 | Unvaccinated | 9,093 | 719 | Baseline | ||
| ChAdOx1-S | None | 41,992 | 807 | 85.6 (83.7–87.3) | ||
| ChAdOx1-S | Any | 0–1 | 2,877 | 47 | 87.3 (82.7–90.7) | |
| ChAdOx1-S | Any | 2–6 | 5,151 | 47 | 93.9 (91.6–95.5) | |
| ChAdOx1-S | BNT162b2 | 7–13 | 6,029 | 24 | 97.6 (96.3–98.4) | |
| ChAdOx1-S | BNT162b2 | 14-34 | 9,664 | 14 | 99.2 (98.6–99.5) | |
| ChAdOx1-S | BNT162b2 | 35–69 | 2,130 | 1 | 99.7 (98.1–100.0) | |
| BNT162b2 | None | 36,093 | 424 | 92.1 (90.8–93.2) | ||
| BNT162b2 | Any | 0–1 | 2,469 | 27 | 93.0 (89.4–95.3) | |
| BNT162b2 | Any | 2–6 | 5,743 | 43 | 95.5 (93.7–96.7) | |
| BNT162b2 | BNT162b2 | 7–13 | 7,843 | 21 | 98.5 (97.6–99.0) | |
| BNT162b2 | BNT162b2 | 14–34 | 17,393 | 45 | 98.6 (98.0–99.0) | |
| BNT162b2 | BNT162b2 | 35–69 | 8,424 | 19 | 98.7 (97.8–99.2) |